Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $4.2 million.

  • Amphastar Pharmaceuticals' Tax Provisions fell 4261.1% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 241.45%. This contributed to the annual value of $46.8 million for FY2024, which is 246.01% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Tax Provisions is $4.2 million, which was down 4261.1% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Tax Provisions ranged from a high of $23.2 million in Q4 2022 and a low of $1.2 million during Q1 2021
  • Moreover, its 5-year median value for Tax Provisions was $6.7 million (2021), whereas its average is $9.0 million.
  • The largest annual percentage gain for Amphastar Pharmaceuticals' Tax Provisions in the last 5 years was 756000.0% (2021), contrasted with its biggest fall of 4934.21% (2021).
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Tax Provisions stood at $7.2 million in 2021, then soared by 222.06% to $23.2 million in 2022, then decreased by 20.02% to $18.5 million in 2023, then increased by 24.88% to $23.1 million in 2024, then plummeted by 82.01% to $4.2 million in 2025.
  • Its Tax Provisions stands at $4.2 million for Q3 2025, versus $8.3 million for Q2 2025 and $5.6 million for Q1 2025.